Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Osteosarcoma is the most common primary bone cancer, primarily affecting young adults.
• The underlying causes of osteosarcoma are complex and not fully understood, necessitating research into novel oncogenic factors.
• Improved therapeutic strategies are urgently needed for osteosarcoma patients, particularly those with metastatic disease.

Purpose of the Study:

• To investigate the role of the oncogene MYC in osteosarcoma.
• To identify MYC targets and their involvement in osteosarcoma pathogenesis.
• To evaluate the therapeutic potential of targeting the MYC/super enhancer axis in osteosarcoma.

Main Methods:

• Analysis of MYC expression in metastatic osteosarcoma samples.
• Identification and analysis of MYC target genes, including super enhancer-bound genes.
• Treatment of osteosarcoma cells with super enhancer inhibitors (THZ1 and JQ1).
• Assessment of cell proliferation, migration, and invasion following inhibitor treatment.

Main Results:

• MYC was found to be significantly upregulated in metastatic osteosarcoma.
• High MYC expression correlated with poorer patient survival.
• MYC binds to most osteosarcoma super enhancer genes.
• Inhibitors THZ1 and JQ1 suppressed osteosarcoma cell proliferation, migration, and invasion.
• THZ1 treatment downregulated key MYC target genes, including CDK6 and TGFB2.

Conclusions:

• The MYC-driven super enhancer signaling pathway is critical for osteosarcoma tumorigenesis.
• Targeting the MYC/super enhancer axis presents a promising therapeutic strategy for osteosarcoma.
• Further research into MYC-driven pathways could lead to more effective osteosarcoma treatments.